Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial
Authors: Ospel Johanna M. , Goyal Mayank , Menon Bijoy K. , Almekhlafi Mohammed A. , Zerna Charlotte , Nogueira Raul G. , McTaggart Ryan A. , Demchuk Andrew M. , Poppe Alexandre Y. , Rempel Jeremy L. , Joshi Manish , Kashani Nima , Heard Kathy , Field Thalia S. , Dowlatshahi Darius , van Adel Brian , Swartz Richard H. , Shah Ruchir , Sauvageau Eric , Puetz Volker , Silver Frank L. , Campbell Bruce , Chapot René , Tymianski Michael , Hill Michael D. ,   on behalf of the ESCAPE-NA1 Investigators
Published: December 2024

BACKGROUND:

In the ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke), treatment with nerinetide was associated with a smaller infarct volume among patients who did not receive intravenous alteplase. We assessed the effect of nerinetide on the surrogate imaging outcome of final infarct volume in patients who did not receive intravenous alteplase and explored predictors of outcome and modifiers of nerinetide’s effect on infarct volume.

METHODS:

ESCAPE-NA1 was a multicenter, randomized trial in which patients with acute stroke with a baseline Alberta Stroke Program Early CT Score >4, undergoing endovascular thrombectomy, were randomized to receive intravenous nerinetide or placebo. Patients not receiving intravenous alteplase were included in this post hoc secondary analysis of the trial data. Final infarct volume was manually segmented on 24-hour noncontrast computed tomography or diffusion-weighted magnetic resonance imaging. Predictors of final infarct volume were identified using multivariable linear regression with cubic-root-transformed infarct volume as the dependent variable. Evidence of treatment-by-predictor interaction was tested by including interaction terms in the model.

RESULTS:

Four hundred forty-six patients (219 who received nerinetide and 227 who received a placebo) out of a total of 1105 enrolled patients were included in this secondary post hoc analysis of the randomized ESCAPE-NA1 trial. Nerinetide was a strong predictor of smaller infarct volume (adjusted β coefficient, −0.35 [95% CI, −0.67 to −0.02]). Other predictors of smaller infarct volume were history of hypertension, good pial collateral filling on multiphase computed tomography angiography, a middle cerebral artery occlusion compared with an internal carotid artery occlusion, lower baseline National Institutes of Health Stroke Scale score, lower baseline systolic blood pressure, lower baseline serum glucose, shorter onset-to-randomization time, and higher Alberta Stroke Program Early CT Score. There was evidence of a treatment-by-systolic blood pressure and treatment-by-anesthesia interaction: nerinetide attenuated the negative effects of elevated baseline (
P
interaction
=0.02) and postdose (
P
interaction
=0.04) systolic blood pressure and use of general anesthesia (
P
interaction
=0.06) on final infarct volume. We observed a marginally significant interaction with reperfusion status, such that nerinetide may attenuate the harmful effect of poor reperfusion status on infarct volume (
P
interaction
=0.08).

CONCLUSIONS:

Nerinetide treatment was strongly associated with smaller final infarct volumes among patients not cotreated with alteplase. The reduction in infarct volume was greater among patients with poor prognostic factors.

REGISTRATION:

URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT02930018.